CymaBay Therapeutics
在场
是其中之一......
CymaBay Therapeutics 是一家在股票代码 CBAY (US) 下上市的公司。
涉及CymaBay Therapeutics的并购和融资。
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (公布2024二月15号).
高管
查看带有其 16 名主要高管的组织结构图
CymaBay Therapeutics 搜索最多的简介
- Sujal Shah, Director, President and Chief Executive Officer
- Robert Wills, Executive Chairman of the Board
- Caroline Loewy, Director
高管在CymaBay Therapeutics变化
- Lewis Stuart, Chief Commercial Officer, 将于 202312月31 退休 (新闻发布的2023十二月22号).
- Ben Kozub 曾任 Vice President, Liver Franchise, 将于 202312月31 升职为 Chief Commercial Officer (新闻发布的2023十二月22号).
创建提醒
跟踪 CymaBay Therapeutics 的高管变动
药店
CymaBay Therapeutics 拥有 1,859 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- MedMen has filed for bankruptcy protection (公布2024四月28号).
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
药店 行业的其他推荐联系人
消息
CymaBay Therapeutics 的最新新闻稿
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
- CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
- Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
- View more press releases Close
通过电子邮件
